Poltreg eyes 2027 milestone as Treg therapies gain big pharma traction

Poltreg's leadership highlights growing big pharma interest in regulatory T lymphocyte therapies, positioning 2027 as a key milestone for the biotech firm. The claim is based on executive statements, with no specific clinical or financial data provided. This signals potential sector momentum but remains an emerging narrative.